The use of bergamot-derived Polyphenol Fraction in Cardiometabolic Risk Prevention and its Possible Mechanisms of Action.

Walker R, Janda E and Mollace V Chp 84; pg 1085-1103,2014

Bergamot (Citrus bergamia Risso et Poiteau) fruits are characterized by a particularly high content and a unique composition of flavonoids, such as neoeriocitrin, neohesperidin, naringin, melitidin and brutieridin. Bergamot juice and its concentrate, highly enriched in polyphenols—here referred to as Bergamot Polyphenol Fraction (BPF)—has been evaluated in experimental and clinical studies. Studies performed in Italy and Australia showed that BPF treatment leads to an important reduction in lipid parameters in the blood of patients with hyperlipidemia ranging from 15 up to 40% for total cholesterol and cholesterol-LDL. A striking reduction (mean 41.0±2.6%) was also observed for plasma triglyceride levels, accompanied by a significant decrease in blood glucose (22.3±1.0%) in a subgroup of patients with metabolic syndrome. Although BPF cannot be proposed as a substitute for statins in patients at high risk of cardiovascular events, it offers an excellent alternative for low-risk and for statin-intolerant patients. The robust performance of BPF in clinical practice against cardiometabolic risk factors can be explained in the light of scientific evidence showing that bergamot flavonoids influence lipid and sugar metabolism acting as 3-hydroxy-3-methlglutaryl coenzyme A (HMG-CoA) reductase inhibitors and AMP kinase (AMPK) activators.

Read All: